Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
ConditionNSCLC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking Union Medical College
About this trial
This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Patients voluntarily join the study and sign an informed consent form for the study.
ECOG PS score 0-3 (patients with PS score 2-3 would be enrolled if due to the tumor disease and anticipated to be improved at investigators' decision).
Histologically documented, stage III, IV non-Small Cell Lung Cancer (according to version 8th of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and previously untreated systematically(excluding local therapy for local lesions or symptomatic relief, palliative radiotherapy, intervention, intrathecal injection, nerve block, etc.).
Disqualifiers
All patients carry activating mutations of EGFR, ALK, ROS1, and RET. (No more mutation test needed).
Small cell lung cancer (including patients with mixed small cell lung cancer and non-small cell lung cancer).
Histopathologically or cytopathologically confirmed non-NSCLC.
Any prior treatment of antibody/drug that targets T-cell coregulatory proteins (not limited to CTLA-4 inhibitors or other agents targeting T cells).
Trial design
Treatments tested in this trial
- Sugemalimab and Chemotherapy
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov